Eli Lilly and Company

Can the General Public Be a Proxy for an “At-Risk” Group in a Patient Preference Study? A Disease Prevention Example in Rheumatoid Arthritis (2024) DiSantostefano RL, Simons G, Englbrecht M, Humphreys JH, Bruce IN, Bywall KS, Radawski C, et al. Journal article Baricitinib as monotherapy for treatment of rheumatoid arthritis: analysis of real-world data (2024) Edwards CJ, Takeuchi T, Finckh A, Kleyer A, Haladyj E, Gerwien JG, Treuer T, et al. Journal article, Review article Different roles of protein biomarkers predicting eGFR trajectories in people with chronic kidney disease and diabetes mellitus: a nationwide retrospective cohort study (2023) Kammer M, Heinzel A, Hu K, Meiselbach H, Gregorich M, Busch M, Duffin KL, et al. Journal article Maximum Acceptable Risk Estimation Based on a Discrete Choice Experiment and a Probabilistic Threshold Technique (2023) Veldwijk J, DiSantostefano RL, Janssen E, Simons G, Englbrecht M, Schölin Bywall K, Radawski C, et al. Journal article Acceptable risks of treatments to prevent rheumatoid arthritis among first-degree relatives: demographic and psychological predictors of risk tolerance (2022) Simons G, Janssen EM, Veldwijk J, Disantostefano RL, Englbrecht M, Radawski C, Valor-Mendez L, et al. Journal article Inter-Reader Consistency and Exclusionary Findings During Radiographic Screening for Phase 3 Trials of Tanezumab in Patients With Osteoarthritis. (2022) Guermazi A, Roemer F, Kompel AJ, Diaz LE, Crema MD, Brown MT, Hickman A, et al. Journal article Exploring preferences of at-risk individuals for preventive treatments for rheumatoid arthritis (2022) Simons G, Bywall KS, Englbrecht M, Johansson EC, Disantostefano RL, Radawski C, Veldwijk J, et al. Journal article Preferences for preventive treatments for rheumatoid arthritis: discrete choice survey in the UK, Germany and Romania (2022) Simons G, Veldwijk J, Disantostefano RL, Englbrecht M, Radawski C, Bywall KS, Mendez LV, et al. Journal article Patient Characteristics and Treatment Patterns in European Pediatric Patients with Psoriasis: A Real-World, Cross-Sectional Study (2022) Sticherling M, Mcpherson T, Laguna RDL, Costanzo A, Reed C, Artime E, Robert C, et al. Journal article Long-term Efficacy and Safety of Up to 108 Weeks of Ixekizumab in Pediatric Patients With Moderate to Severe Plaque Psoriasis: The IXORA-PEDS Randomized Clinical Trial. (2022) Paller AS, Seyger MMB, Magarinos GA, Pinter A, Cather JC, Rodriguez-Capriles C, Zhu D, et al. Journal article